Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years?

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where NeoGenomics, Inc. (NASDAQ:NEO) stands against the other profitable stocks.

The stock market has a long history of generating wealth for investors. While past performance doesn't guarantee future results, studying successful companies can provide valuable insights. By understanding the factors that drive these companies' growth, we can potentially make better investment decisions in the future. It's important to remember that investing involves risk, and conducting thorough research is crucial before making any investment decisions.

Investors frequently overlook revenue in favor of profitability when evaluating stocks. Profit is what's left over after all costs are paid. Revenue is the total amount of goods and services sold. Because it is essential to determine if a business is a growth stock or a value one, profitability is important. To learn more about growth stocks, see 12 Best Growth Stocks to Buy and Hold in 2024. You can also discover some undervalued value stocks by reading 11 Oversold Value Stocks To Buy Now.

The U.S. stock market has seen several major events since 2000, including the dot-com boom and fall, the 2008 financial crisis, a tech boom with trillion-dollar values, and the 2020 pandemic crisis. The S&P's broader market index produced double-digit yearly returns thirteen times between 2003 and 2023. This strong performance can be largely attributed to the phenomenal returns generated by technology stocks, which significantly boosted the overall return of the large-cap market.

According to a recent estimate, the aggregate market value of the top seven S&P 500 corporations is almost double that of the Japanese market. The head of topical research and global economics, Jim Reid, cautions that this is the most concentrated the US market has ever been.

As interest in growth stocks increases due to the hype surrounding AI and the prospect of rate cuts, these companies' fortunes are expected to soar. To satisfy market demand, businesses are making significant investments in AI. AI's impact on altering work patterns was highlighted by Satya Nadella du. According to them,:

“A growing body of evidence makes clear the role AI will play in transforming work. Our own research, as well as external studies, show as much as 70% improvement in productivity, using generative AI for specific work tasks."

Our Methodology 

To identify the most profitable stocks, we looked at the 20-year annualized returns of publicly traded companies in the US market from 2004 to 2024 and selected and ranked those with the highest 20-year annualized returns.

An oncologist in a hospital laboratory discussing the results of a clinical service test.

NeoGenomics, Inc. (NASDAQ:NEO)

20-Year Annualized Return: 20.77% 

NeoGenomics, Inc. (NASDAQ:NEO) is a leading provider of cancer-focused genetic testing services and global oncology contract research services. NeoGenomics recently launched a Comprehensive Lung Solution and expanded hematopathology services at ASCO 2024. They presented advancements in spatial biology and next-generation sequencing at AACR 2024, alongside highlighting the EPDegTM platform for targeting challenging proteins.

NeoGenomics reported improvements in Q1 2024 despite a net loss of $27 million, showing a 12% reduction from the previous year and indicating progress toward profitability. The company's adjusted gross profit rose by 19% to $71 million, which was driven by effective cost management and pricing strategies.

NeoGenomics, Inc. (NASDAQ:NEO)'s total revenue in the period increased by 14% year-over-year to $156 million which was fueled by a robust performance in the Clinical Services segment, which grew by 17% to $135 million. This growth was supported by a rise in average revenue per clinical test and strong adoption of Next Generation Sequencing (NGS) technologies, contributing to over 50% growth in NGS revenue. Despite challenges in the Advanced Diagnostics segment, NeoGenomics' strategic focus on expanding its testing capabilities and improving operational efficiencies has positioned it well in the competitive oncology diagnostics market.

In Q1 2024, there were 12 hedge fund holders in the company, down from 20 in the previous quarter. Braidwell LP held the largest share in the company with 103,580,000 worth $82,605,050. Analysts rate NeoGenomics stock as a "Strong Buy," with an average 12-month price target of $19.78. This represents a potential upside of 44.06% from the current price of $13.73, with price forecasts ranging from $17 to $26.

Overall NEO ranks 11th on our list of the most profitable stocks of the last 20 years. You can visit 20 Most Profitable Stocks of the Last 20 Years to see the other profitable stocks that are on hedge funds’ radar. While we acknowledge the potential of NEO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than NEO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: Analyst Sees a New $25 Billion "Opportunity" for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.

 

Disclosure: None. This article is originally published at Insider Monkey.